| 6.11 -0.04 (-0.65%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.35 | 1-year : | 9.75 |
| Resists | First : | 7.15 | Second : | 8.35 |
| Pivot price | 5.61 |
|||
| Supports | First : | 5.82 | Second : | 5 |
| MAs | MA(5) : | 6.03 |
MA(20) : | 5.67 |
| MA(100) : | 6.26 |
MA(250) : | 5.84 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 76.1 |
D(3) : | 73.3 |
| RSI | RSI(14): 51.7  |
|||
| 52-week | High : | 9.82 | Low : | 3.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VRCA ] has closed below upper band by 14.1%. Bollinger Bands are 32.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.35 - 6.38 | 6.38 - 6.41 |
| Low: | 5.88 - 5.92 | 5.92 - 5.96 |
| Close: | 6.05 - 6.11 | 6.11 - 6.16 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Fri, 13 Mar 2026
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm
Wed, 11 Mar 2026
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Wed, 11 Mar 2026
VRCA: Revenue surged 368% in 2025, costs fell, debt was retired, and global expansion accelerated - TradingView
Wed, 11 Mar 2026
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Wed, 11 Mar 2026
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
Wed, 11 Mar 2026
[10-K] Verrica Pharmaceuticals Inc. Files Annual Report | VRCA SEC Filing - Form 10-K - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 51.8 (%) |
| Held by Institutions | 32.6 (%) |
| Shares Short | 385 (K) |
| Shares Short P.Month | 299 (K) |
| EPS | -2.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.8 |
| Profit Margin | -84.4 % |
| Operating Margin | 11.3 % |
| Return on Assets (ttm) | -26.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.29 |
| Sales Per Share | 1.92 |
| EBITDA (p.s.) | -0.94 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -29 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -2.13 |
| PEG Ratio | 0 |
| Price to Book value | -3.4 |
| Price to Sales | 3.16 |
| Price to Cash Flow | -3.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|